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Jelena Stevanovic,́ PhD*, Maarten J. Postma, PhD, Hoa H. Le, PhD
University of Groningen, Groningen, the NetherlandsA B S T R A C TBackground: Patient self-testing (PST) and/or patient self-manage-
ment (PSM) might provide better coagulation care than monitoring at
specialized anticoagulation centers. Yet, it remains an underused
strategy in the Netherlands. Methods: Budget-impact analyses of
current and new market-share scenarios of PST and/or PSM com-
pared with monitoring at specialized centers were performed for a
national cohort of 260,338 patients requiring long-term anticoagu-
lation testing. A health care payer perspective and 1- to 5-year time
horizons were applied. The occurrence of thromboembolic and
hemorrhagic complications in the aforementioned patient popula-
tion was assessed in a Markov model. Dutch-speciﬁc costs were
applied, next to effectiveness data derived from a meta-analysis on
PST and/or PSM. Sensitivity and scenario analyses were performed
to assess uncertainty on budget-impact analysis results. Results:
Increasing PST and/or PSM usage in the national cohort from




ndence to: Jelena Stevanovic ́, Antonius Deusinglaaafter the ﬁrst year to €184 million after 5 years. Further increases
in the use of PST and/or PSM produced greater savings. Sensi-
tivity analyses revealed budget-impact model sensitivity to the
baseline and relative risks of thromboembolic complications.
Unfavorable budget impact was found in scenarios exploring an
increase in the use of PST alone as well as an increase in the
market share of PST and PSM in patients with atrial ﬁbrillation.
Conclusions: Overall study ﬁndings indicated that PST and PSM are
more favorable alternatives to monitoring at specialized centers in
patients without atrial ﬁbrillation.
Keywords: anticoagulation, budget-impact analysis, patient self-
management, patient self-testing, point-of-care devices.
& 2016 Published by Elsevier Inc. on behalf of International Society for
Pharmacoeconomics and Outcomes Research (ISPOR).Introduction
Oral anticoagulation therapy (OAT) with vitamin K antagonists
(VKAs) has been shown to reduce the risks of thromboembolic
events in a number of clinical situations [1]. In the Netherlands,
indications for OAT include patients with atrial ﬁbrillation (AF),
arterial diseases (e.g., cardiomyopathy, coronary syndromes and
surgery, vascular surgery, and cerebral embolism), heart valve
replacement, venous thromboembolism, and some other speciﬁc
diseases [2]. Patients with AF represent most of the patients
requiring OAT (i.e., 62% in the Netherlands). With the increase in
the number of patients with AF, it is not surprising that the
number of patients requiring OAT has increased as well over the
past decades in Western countries [2]. Furthermore, the popula-
tion of patients in need of OAT is projected to increase further in
the coming decades [3,4]. This is partly due to the aging
population in Western countries and the observation that both
the incidence and the prevalence of AF increases with increasing
age [5].
Although warfarin is commonly used worldwide, acenocou-
marol and phenprocoumon (to a lesser extent) are the VKAs of
ﬁrst choice in the Netherlands. Prophylaxis with VKAs is aneffective strategy, but it has some shortcomings, including multi-
ple interactions with food and other drugs as well as interindi-
vidual and intraindividual variability in pharmacodynamics [6,7].
As a result, regular monitoring is required to maintain the
international normalized ratio (INR) within the therapeutic range.
INR testing is typically performed at specialized anticoagulation
testing centers, adding to the cumbersomeness of VKA use for
the patients. Notably, point-of-care (PoC) devices allow for
patient self-testing (PST), in which trained patients can perform
the INR test but still inform his or her health care provider for
subsequent advice on anticoagulant dosing, or even patient self-
management (PSM), with trained patients performing the INR
test, interpreting the results, and adjusting dosing accordingly.
In agreement with the increasing number of patients with
indications for OAT, the number of patients using INR testing in
the Netherlands has increased from approximately 320,000 in
2002 to 430,000 in 2012 [2]. Again, this trend is expected to
continue in the coming years with the aging population. Also,
between 2007 and 2011, the annual incidence of AF has steadily
increased from less than 40,000 in 2008 to 56,000 in 2012 [2].
These ﬁgures, however, may still underrepresent the actual
number of patients in need of OAT because many eligibleon behalf of International Society for Pharmacoeconomics and
n 1, 9713 AV Groningen, The Netherlands.
V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 3 8 3 – 3 9 0384patients do not receive anticoagulation because of concerns of
the patients or concerns of their physicians of their INR values
being outside the therapeutic range [8–12]. PoC testing may also
address this issue. In line with international ﬁndings [13,14], PST
and/or PSM might lead to better coagulation care in the Nether-
lands compared with regular monitoring in specialized antico-
agulation centers [2]. This may be due in part to the convenience
of use, resulting in more frequent testing, which is associated
with greater time in therapeutic range (TTR) [15]. Also, ﬁndings
from meta-analytical studies suggest that PST and/or PSM com-
pared with regular monitoring have similar risks of bleedings but
reduced risks of thromboembolic events and all-cause mortality
[13]. Finally, it has been reported that the patient empowerment
inherent in PoC strategies in itself already directly reduces the
risks of complications and death even in the theoretical sheer
absence of any measurable increase in the quality of the anti-
coagulation control [16]. Despite these positive results, the use
of PST and/or PSM remains an underused strategy in the
Netherlands.
Eligible patients for PST and/or PSM include all those on long-
term OAT (regardless of indication) who have passed the required
training. To date, the estimated number of patients on long-term
OAT in the Netherlands is approaching 260,338. In the current
situation, 15.4% of this population uses PST and/or PSM [2]. In this
study, we assessed the budget impact of the current situation and
new scenarios in which PST and/or PSM represent 50%, 75%, and
100% of INR monitoring in the Netherlands.Methods
A budget-impact analysis (BIA) was performed using a patient
cohort approach. Patients in the cohort may exit the model after
death, but no new patients enter the model (closed model). The
perspective of the study is that of a health care payer. In the
present analysis, the patient cohort includes all patients who
require anticoagulation monitoring for OAT for any clinical
indication.
The design and reporting of study outcomes followed the
recommendations of the International Society for Pharmacoeco-
nomics and Outcomes Research for BIAs Task Force [17,18].
Model Structure
Patients indicated for OAT are at risk of hemorrhagic and
thromboembolic events. To incorporate the course of disease in
the BIA, a Markov model was developed. This model includes the
following health states: no complications, thromboembolic com-
plications, hemorrhagic complications, and death (see AppendixTable 1 – Annual risks of clinical events for use in the M
analyses.
Clinical events Specialized center
Annual baseline risk (%)*
Thromboembolic event 3.22 (1.50–4.94)
Hemorrhagic event 2.84 (1.16–4.52)
Death 2.87 (1.01–4.74)
Note. 95% CI limits of risk estimates are shown in parentheses. Upper an
analysis.
CI, conﬁdence interval; PSM, patient self-management; PST, patient self
* Estimated through a random-effects meta-analysis of annual risks for
† Adapted from the meta-analysis of individual patient data on self-mon
‡ Estimated by taking the product of the relative risks reported by Henegh
random-effects meta-analysis of annual risks for patients using anticoFig. 1 in Supplemental Materials found at http://dx.doi.org/10.
1016/j.jval.2015.12.017). A cycle length of 1 year was used. The
cumulative budget impact of the cohort was assessed each year
up to 5 years. Patients enter the model in the “no complications”
health state.
In the base-case analysis, transition probabilities for throm-
boembolic and hemorrhagic complications and death were based
on a systematic review and meta-analysis of individual patient
data on self-monitoring of oral anticoagulation by Heneghan
et al. [14]. This study estimated the relative risks (RRs) of
thromboembolic and hemorrhagic complications and death
between testing at anticoagulation centers and PST and/or PSM
for all indications of OAT (Table 1). To assign transition proba-
bilities for each testing strategy, baseline risks for patients
visiting anticoagulation centers/clinics were also needed. Data
on the number of events and the duration of follow-up for this
group were taken from studies by Menéndez-Jándula et al. [19],
Fitzmaurice et al. [20], Matchar et al. [21], and Siebenfofer et al.
[22] (see Appendix Table 1 in Supplemental Materials found at
http://dx.doi.org/10.1016/j.jval.2015.12.017). These studies were
selected because they were included in the study by Heneghan
et al. [14]. To estimate baseline risks of complications and death,
we conducted a meta-analysis on the aforementioned studies in
the statistical program R 3.0.2, using the “metafor” package
(Table 1) [19–24]. Because the study populations are not homoge-
neous across the studies and do not ﬁt the assumption of a ﬁxed-
effect model, a random-effect model was applied.
Annual risks of complications and death for the PST and/or
PSM group were calculated by taking the product of the RRs
reported by Heneghan et al. [14] and the baseline risks were
estimated through a random-effect model (Table 1). In addition,
age-speciﬁc background mortality rates for the Netherlands for
2012 were used to estimate the transition from “no complica-
tions” to “death” [25].Cost Parameters
Costs associated with thromboembolic and hemorrhagic compli-
cations were collected from published Dutch studies. All costs
were inﬂated to 2013 levels using the harmonized index for
consumer product for the health sector for the Netherlands [26].
Costs for thromboembolic events were derived from costs of
ischemic stroke [27], myocardial infarction [28], and pulmonary
embolism [29], with contributions of 71.43%, 24.32%, and 4.25%,
respectively, to the overall estimate [30]. Cerebral hemorrhage
[31], gastrointestinal bleeding [32], and other bleedings [32] were
assumed to represent 10.66%, 30.46%, and 58.88% of the costs,
respectively, associated with hemorrhagic complications [30]. Forarkov model—base-case and univariate sensitivity
PST and/or PSM
Relative risk (%)† Annual risk (%)‡
0.44 (0.17–1.14) 1.42 (0.26–5.63)
0.91 (0.74–1.12) 2.58 (0.86–5.06)
0.82 (0.52–1.28) 2.35 (0.53–6.07)
d lower 95% CI limits were used as inputs for univariate sensitivity
-testing.
patients using anticoagulation testing centers.
itoring of oral anticoagulation by Heneghan et al. [14].
an et al. [14] and the baseline annual risks estimated by the authors’
agulation testing centers.
V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 3 8 3 – 3 9 0 385each complication, costs were differentiated between ﬁrst and
subsequent years in the analysis, given the different nature of
complications between these years. No subsequent-year cost was
assumed for pulmonary embolism and bleeding events though.
Furthermore, death was not associated with any additional cost.
The weighted costs of thromboembolic complications were
€41,866 for the ﬁrst year and €8,750 for subsequent years. For
hemorrhagic complications, the weighted averages were €9748
and €1263 for ﬁrst and subsequent years, respectively (Table 2).
The acquisition cost of VKAs and anticoagulation monitoring
are presented in Table 2. The cost of VKAs was estimated as a
weighted average cost of acenocoumarol 1mg and phenprocoum







Stroke [27] 50,828 11,800
Myocardial infarction [28] 22.015 1.338




Cerebral hemorrhage [27,31]‡ 38,417 11,800
Gastrointestinal bleeding [32] 7,120 0





VKA [33] 16 16
Specialized centers 248 248
Blood sampling & INR
measurements at centers [34]‖
181 181
Additional tariff for blood
sampling at home [34]¶
67 67
PST and/or PSM 958 749
Initial training & instruction
[34]
396 0
Monitoring & supervision [34]# 562 749
Additional tariff for phone
consultation for PST only [32]**
210 210
INR, international normalized ratio; PSM, patient self-manage-
ment; PST, patient self-testing; VKA, vitamin K antagonist.
* Cost estimate of pulmonary embolism from the original source
was corrected to exclude the cost of INR testing and coumarines.
† On the basis of the assumption that the cost of a thromboem-
bolic event will be a composite of the costs related to stroke,
myocardial infarction, and pulmonary embolism, with contribu-
tions of 71.4%, 24.3%, and 4.2%, respectively, to the overall
estimate.
‡ Cost estimate of cerebral hemorrhage from the original source
was corrected to exclude the costs of home help and private
transportation costs.
§ On the basis of the assumption that the cost of a hemorrhagic
event will be a composite of the costs related to cerebral
hemorrhage, gastrointestinal bleeding, and other major bleeding,
with contributions of 10.7%, 30.5%, and 58.9%, respectively, to the
overall estimate.
‖ Assuming 21.1 tests per year [2].
¶ Assuming 8.6 home blood samplings per year [2].
# Assuming three supervision sessions in the ﬁrst year and four
supervision sessions in the subsequent years.
** Assuming 12 phone consultations on dosing per year for
patients who only self-test.respectively). The annual cost of VKAs was estimated at €16.06 [33].
Anticoagulation testing at centers may involve blood sampling at
the centers or at home. For blood sampling and measurement at
testing centers, 21.1 INR tests per patient per year were assumed [2].
In addition, there were 8.6 home blood samplings per patient per
year for the same patient group as those tested in the center [2]. The
annual cost of monitoring at testing centers is the same for each
year and estimated to be €248 [34].
The ﬁrst-year cost of PST and/or PSM consisted of the costs of
the device and one initial training session and three supervision
sessions. Subsequent years of use required quarterly supervision
sessions. The costs of the ﬁrst and subsequent years were
estimated to be €958 and €749, respectively [34]. Here, no addi-
tional costs were assumed for dosing given that these patients
receive information for possible adjustments in their dose by e-
mail or speciﬁc software.
Budget-Impact Analysis
In the analysis, a cohort population size was evaluated at 260,338.
This cohort size represents an estimate of all patients requiring
long-term anticoagulation testing for OAT for any indication on a
national level for the Netherlands. Using estimates from the
Federation of Dutch Thrombosis Services (“Federatie Nederlandse
Trombosediensten”) Report 2012, the current share of PST and/or
PSM among patients on long-term monitoring was assumed to be
15.4% [2]. This current situation was evaluated against potential
new market penetration scenarios of 50%, 75%, and 100% for PST
and/or PSM. The BIA was evaluated for each year up to 5 years.
Costs were not discounted as recommended by the International
Society for Pharmacoeconomics and Outcomes Research Task
Force for BIAs [17].
Sensitivity Analysis
To examine the impact of uncertainty in key model parameters (i.
e., baseline risks and RRs of complications and death and cost
parameters), univariate sensitivity analyses were performed on 5-
year BIA results considering a market penetration scenario of 50%
in Dutch patients on long-term OAT. Here, each parameter was
varied over the 95% conﬁdence interval (CI) while holding all other
parameters constant. Where CI or standard error was unavailable,
the standard error was assumed to be 25% of the mean.
Scenario Analyses
Three scenario analyses were conducted to investigate the
impact of increasing the market share of PST and/or PSM up to
50% under different decision analytic settings. Scenario 1
explored a linear increase in the uptake of PST and/or PSM from
the current 15.4% to the expected 50% in 5 years. In scenario 2, an
increase in the market share of PST alone from the current 6.16%
(i.e., 40% of all patients with PoC devices) to 50% was explored.
Here, transition probabilities for thromboembolic and hemorrha-
gic complications in the Markov model were based on the RRs of
using PST alone compared with testing at specialized centers
reported by Heneghan et al., and the baseline risks estimated
through a random-effect model (see Appendix Table 2 in Supple-
mental Materials found at http://dx.doi.org/10.1016/j.jval.2015.12.
017). In this scenario, the costs of PST alone were assumed to be
associated with an additional €210 per year compared with the
PST and PSM strategy, reﬂecting consultations for dosing regimen
adjustments.
Finally, the BIA of increasing the market share of PST and/or
PSM from the assumed 15.4% to 50% in patients with AF was
explored in scenario 3. In this scenario, it was assumed that 62%
of the patients on long-term OAT are affected with AF; thus, a
cohort population size was evaluated at 161,410 patients. Here,
V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 3 8 3 – 3 9 0386transition probabilities in the Markov model were based on the
RRs of events for PST and/or PSM compared with testing in
anticoagulation centers, assessed in patients with AF (see
Appendix Table 2).Results
Base-Case Results
The allocation of total costs per patient associated with INR
monitoring in specialized anticoagulation centers and with PoC
devices in a time horizon of 1 to 5 years is detailed in Appendix
Table 3 in Supplemental Materials found at http://dx.doi.org/10.
1016/j.jval.2015.12.017. Monitoring-related costs were higher than
event-related costs only in the ﬁrst year in patients conducting
INR testing with PoC devices. Costs associated with thromboem-
bolic and hemorrhagic events were responsible for the vast
majority of total costs with PoC devices in the longer time
horizons and in all time horizons in patients conducting testing
in specialized centers. Expanding the aforementioned ﬁndings to
a Dutch national cohort of 260,338 patients using long-term
anticoagulation testing, a current situation of 15.4% using PST
and/or PSM with PoC devices resulted in cumulative costs of €486
million, €1.00 billion, €1.54 billion, €2.11 billion, and €2.70 billion
in the ﬁrst, second, third, fourth, and ﬁfth year, respectively
(Fig. 1). On increasing the use of PST and/or PSM to 50% in the ﬁrst
year, a cost saving of €8 million from the health care budget could
be observed. The savings increased exponentially each year,
reaching an estimated saving of €184 million after the ﬁfth year.
Similarly, increasing PST and/or PSM market penetration to 75%
and 100% produced correspondingly greater 5-year cumulative
savings of €317 and €450 million, respectively. Although it is not
likely that PST and/or PSM will completely replace INR testing at
specialized anticoagulation centers, this latter scenario illustrates
the potential maximum savings in long-term utilization.Fig. 1 – Budget-impact analysis from year 1 to year 5 of current
millions). Bars above the horizontal axis present cumulative cos
PST and/or PSM (i.e., 50% and 75%). Bars below the horizontal a
market-share scenarios. PSM, patient self-management; PST, paSensitivity Analysis
The results of the univariate sensitivity analyses show the impact
of uncertainty surrounding the key model parameters, illustrating
that the RR and the baseline risk of thromboembolic complications
had the highest impact on the BIA results (Fig. 2). Speciﬁcally,
when the RR of thromboembolic complications would drop to the
lower limit of the 95% CI, BIA results would indicate savings of
€382 million. At risks increasing to the upper limits of 95% CIs, an
expenditure of €302 million from the health care budget would be
observed. The univariate sensitivity analyses also found that the
BIA results were sensitive to the uncertainty around the cost
parameters. Yet, these results generally favored an increasing
market penetration of PST and/or PSM.
Scenario Analyses
The results of scenario analyses are presented in Table 3. In
scenario 1, a linear increase in the uptake of PST and/or PSM from
the current 15.4% to the expected 50% indicated savings ranging
from €2 million after the ﬁrst year to €184 million cumulatively
after the ﬁfth year. Increasing the market share of PST alone from
the current 6.16% to 50% resulted in expenditures from €57
million after the ﬁrst year to €123 million cumulatively after the
ﬁfth year (scenario 2). Finally, increasing the market share of PST
and/or PSM in a cohort of 161,410 patients with AF indicated an
expenditure of €15 million after the ﬁrst year, but resulted in
cumulative savings of €2 million after 5 years (scenario 3).Discussion
Our study presents a BIA of the current situation and new varying
market penetration scenarios of anticoagulation monitoring with
PST and/or PSM compared with monitoring at specialized anti-
coagulation centers in the Netherlands. Our ﬁndings in the base-
case analysis indicated that increasing PST and/or PSM usage forand new market share scenarios for PST and/or PSM (in
ts of current (i.e., 15%) and new market-share scenarios for
xis present the differences in cost between new and current
tient self-testing.
Fig. 2 – Tornado diagram illustrating results from sensitivity analyses for budget-impact analysis in a 5-year horizon
considering a market penetration scenario of 50% for PST and/or PSM in a Dutch cohort of 260,338 patients (in millions). Gray
bars denote the inﬂuence of the high value of the 95% conﬁdence interval (CI) range, and black bars denote the inﬂuence of the
low value for parameters investigated. PSM, patient self-management; PST, patient self-testing.
V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 3 8 3 – 3 9 0 387anticoagulation testing from the current 15.4% to 50%, 75%, and
100% would lead to signiﬁcant savings in all analyzed scenarios.
Even though INR testing is 3.9 times and 3.0 times more costly for
PST and/or PSM compared with testing at specialized anticoagu-
lation centers during the ﬁrst year and subsequent years, cost
saving was still observed when considering total direct medical
costs due to considerably higher event-related costs in later























Note. Scenario 1 explores a linear increase in the uptake of PST and/or
explores an increase in the market share of PST alone from 6.16% to 50%
PSM in patients with AF from 15.4% to 50%.
AF, atrial ﬁbrillation; NA, not applicable; PSM, patient self-management;
* Values are rounded.
† Patients with AF only.thromboembolic and hemorrhagic complications associated with
high medical costs. In fact, increasing the number of patients
switching from conventional testing to PST and/or PSM by
increasing market penetration produced even greater savings in
the time horizon of 5 years. For example, considering a national-
level cohort population, potential maximum savings of €450
million over the current situation may be observed in 5 years.


























PSM from the current 15.4% to the expected 50% in 5 y. Scenario 2
. Scenario 3 explores an increase in the market share of PST and/or
PST, patient self-testing.
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represent 50% of all patients requiring long-term INR testing—a
ﬁgure that is quite attainable in the coming years—savings range
from €8 million after the ﬁrst year to €184 million after 5 years.
These analyses demonstrated the value of PST and/or PSM
strategy with PoC devices in the Netherlands. Univariate sensi-
tivity analyses revealed the major impact of uncertainty in
baseline and relative thromboembolic risk on the BIA results.
The relevance of the uncertainty in the baseline thromboembolic
risk can be directly attributed to its impact on the occurrence of
stroke, myocardial infarction, and pulmonary embolism events
and their related costs of treatment reaching in the ﬁrst year and
follow-up years a weighted average cost of €41,866 and €8,750 per
patient, respectively.
Finally, this study observed potential unfavorable budget
impact of increasing market shares of PST alone, as well as
increasing market shares of PST and/or PSM in patients with AF
on long-term OAT (scenarios 2 and 3). Greater expenditures
associated with increasing market shares of PST alone in scenario
2 are due to not only the higher cost of PST strategy compared
with PST and PSM combined but also costs associated with the
lower number of prevented complications in comparison to the
base-case scenario. The ﬁndings in scenario 3 may be attributed
to the lower number of thromboembolic complications prevented
in comparison to the base-case scenario, and the greater number
of hemorrhagic complications with PST and/or PSM than with
monitoring in specialized centers, which are associated with
high costs.
Comparison with Other Studies
To our knowledge, published economic evaluations of PST and/or
PSM compared with monitoring at specialized anticoagulation
centers or with routine clinic-based care are all cost-effectiveness
analyses (CEAs). This hampers a direct comparison of our study
ﬁndings with the ones from these other studies. Yet, there is a
general agreement in the conclusions of the available CEAs with
our study results regarding the preference for PST and/or PSM for
long-term use. However, all those CEAs indicate higher cost of
PST and/or PSM compared with testing in anticoagulation cen-
ters, routine clinics, or by physicians. Speciﬁcally, Regier et al. [35]
found the self-managed anticoagulation to be a more cost-
effective alternative compared with physician-managed antico-
agulation from the Canadian health care payer perspective in a 5-
year time horizon with an incremental cost-effectiveness ratio
(ICER) of Can$14,129 per quality-adjusted life-year (QALY) [35]. In
the same study, when the use of self-management was limited to
a 1-year time horizon, an ICER of Can$236,667 per QALY was
estimated [35]. Furthermore, in the study by Lafata et al. [36], self-
testing in a US setting was found to be a cost-effective alternative
to testing in anticoagulation clinics, with an ICER of $24,818 per
event avoided in a 5-year time horizon. Finally, Jowett et al. [37]
found PSM compared with routine clinic-based monitoring
unlikely to be cost-effective from the UK health care system
perspective in a 1-year time horizon (i.e., ICER of £32,716 per
QALY). The key driving parameters of cost across these CEAs are
detailed in Appendix Table 4 in Supplemental Materials found at
http://dx.doi.org/10.1016/j.jval.2015.12.017. The results of CEAs
may be mainly attributed to greater local costs of the PST/PSM
strategy compared with the alternative testing strategy and
sources of effectiveness data. Across all the aforementioned
studies, the total cost of testing with PST and/or PSM outweighed
the cost of alternative strategy. These ﬁndings were mainly
driven by the effectiveness data used to estimate the number of
thromboembolic and hemorrhagic complications and death, their
associated costs, and costs of testing strategies. In particular,
Jowett et al. used patient-level data from a randomized controlledtrial (RCT) by Fitzmaurice et al. [20] that if summarized
(Heneghan et al. [14]) indicate greater RRs of thromboembolic
and hemorrhagic events for PST and/or PSM compared with the
alternative testing strategy. In the studies by Regier et al. and
Lafata et al., the number of thromboembolic and hemorrhagic
events occurring while using the investigated testing strategies
was estimated on the basis of the TTR achieved (i.e., 71.8% vs.
63.2% and 89% vs. 65%, respectively, on PST/PSM vs alternative
testing) and the risk of those events conditional on the TTR. This
estimation resulted in a relatively low number of events avoided
with PST and/or PSM compared with the alternative testing
strategy. Regier et al. found only 0.72 thrombotic and 0.17
hemorrhagic events avoided per 100 patients with PST and/or
PSM in the ﬁrst year, while after 5 years this summed up to 3.5
and 0.79 events avoided, respectively. Similarly, Lafata et al.
observed in total 4.9 events avoided per 100 patients with PST
and/or PSM compared with the alternative testing strategy over a
5-year time horizon.
Strengths and Limitations
Inferences drawn from BIAs are related to the quality of the
evidence that goes into the model. One point of strength of the
current analysis is that effectiveness inputs are based on a
consistent synthesis of evidence [14]. In the hierarchy of evidence
pyramid, evidence synthesis of multiple trials resides above
evidence from a single RCT [38,39]. Yet, it must be pointed out
that no studies investigating the effectiveness of PST and/or PSM
have been conducted in the Netherlands. In the present analysis,
effectiveness measures were derived from studies investigating
PST and/or PSM versus specialized testing centers for all OAT
indications [19–22]. Because of the heterogeneity between the
studies, a random-effect model was used to establish baseline
risks for thromboembolic and hemorrhagic complications for
patients using anticoagulation testing centers. To estimate risks
of complications for patients using PST and/or PSM, RR reduction
was applied as reported by Heneghan et al. [14]. In addition, an
advantage of this approach over relying on data from a single
RCT is that all indications for OAT were considered. This reﬂects
a more complete assessment of the impact of different strategies
on costs of anticoagulation testing. Also, we examined the impact
of uncertainty surrounding the key model parameters on BIA
results. Finally, to explore the impact of increasing market shares
of PoC devices on the health care budget in speciﬁc settings, such
as the use of PST alone and the use of PoC in patients with AF,
scenario analyses were conducted.
Our study has several limitations. First, only direct medical
costs were considered in our analyses and no costs related to
productivity loss were included. Costs related to productivity loss
may be reduced for patients using PST and/or PSM because they
may miss less work as a result of greater effectiveness in the
prevention of complications (Table 1). Also, testing at home with
a PoC device avoids work time lost because it eliminates the need
for travel and waiting time at testing centers. Yet, one caveat in
considering productivity loss among patients indicated for OAT is
that many are elderly patients, such as those with AF, and may
already be retired. Notably, although the current estimates on
cost savings in the 5-year time horizon applied are substantial,
they may still reﬂect an underestimation of the true savings
in the patient groups in whom accounting for productivity loss is
considered to be appropriate (i.e., patients o65 years of age).
Second, our model design may also be a factor for underestimation.
In this analysis, clinical events and associated costs were fol-
lowed for a cohort of patients for up to 5 years. An alternative
approach is to dynamically add new patients each year as
estimated by annual incidence rates. Such an approach would
include more patients in the analysis because the incidence rates
V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 3 8 3 – 3 9 0 389are expected to continue to rise in the coming decades [3]. Third,
the recent introduction of novel oral anticoagulants, such as
dabigatran, rivaroxaban, and apixaban, in the Dutch market for
use in patients with some of the indications for OAT was not
accounted for in our study [40,41].
Currently, such a comparison between novel oral anticoagu-
lants and VKAs managed with PST and/or PSM is hampered
given the lack of RCTs between the two comparators as well as
data on the current use of novel oral anticoagulants in clinical
practice in the Netherlands. Fourth, future uptake of the PST
and/or PSM strategy (i.e., 50%, 75%, and 100%) in this study was
based on an assumption. Yet, it may be more informative to
estimate this in relation to the factors inﬂuencing its current
low market share, for example, because of patients’ preferences.
In particular, there are indications by some Dutch experts that
some patients prefer to have more regular contact with hospi-
tals/anticoagulation centers rather than to self-manage. In
addition, they indicate that an increase in the uptake of PoC
strategies could be achieved if these strategies would be actively
offered to patients as an alternative to management in the
clinics, which currently is not the case. Finally, because of data
limitations, estimates of the baseline risks used in this
study could not be supported by local real-life data. Such
information is needed given that the baseline information used
from the RCTs is commonly based on highly selected patient
populations whose characteristics may deviate from the usual
practice.
The potential deviation from the Dutch patient population
indicated for long-term OAT may concern eligibility and exclu-
sion criteria for PST and/or PSM. For example, one of the RCTs
included only those patients who were 60 years or older [22],
and another study excluded patients who failed to attend a
training for PST/PSM [19]. This differs from the Dutch practice in
which patients are eligible for PST and/or PSM if they are on
long-term OAT and have passed the required training. Further-
more, the TTR observed at 1 year for patients visiting anti-
coagulation centers/clinics in the RCTs was in range from 61% to
68.8%. In the Dutch health care system, the quality of anti-
coagulation care performed by specialized anticoagulation test-
ing centers is considered high, with approximately 80% of the
patients having their measurements within the INR limits [2].
This study did not aim to model a possible association between
the proportion of TTR with bleeding and thromboembolic risk,
and one could expect that such an association would lead to
lower baseline risk in Dutch patients and consequently
greater expenditure for patients switching to PST and/or
PSM. In conclusion, overall study ﬁndings indicated that
compared with regular anticoagulation testing at specialized
centers, PST and PSM with PoC devices can lead to cost
savings in patients without AF. In addition, our study indicated
that using PoC devices solely for PST resulted in greater
expenditures compared with testing in anticoagulation clinics;
thus, this strategy may need to be disregarded. Further research
is needed to explore this strategy in other indications and
conﬁrm the aforementioned ﬁndings with local real-life data.
Given the increasing number of patients with indications for
OAT and high treatment costs of thromboembolic events, the
choice of the optimal monitoring and managing strategy is of high
importance, both regarding the costs considered here and the
health effects. Further research should be directed at performing
formal CEAs comparing the two strategies in speciﬁc indications
(AF, deep vein thrombosis, etc.). This would provide additional
insights into both societal costs and long-term effects of those
strategies on health, such as expressed in terms of QALYs.
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